[2021] UAE Heart Failure Treatment Drugs Market Size & Trends expected to reach US$ 97.5 Million With CAGR of 6.5% by 2027 – Coherent Market Insights

SEATTLE, April 29, 2021, (PHARMIWEB) — UAE Heart Failure Treatment Drugs Market analysis

Impact of COVID-19 epidemic

Following the COVID-19 outbreak, the lockdowns in the UAE had put the burden of economy on the public and private healthcare industry. Problems such as reduced patient footfalls along with additional equipment, manpower, consumables, are been faced by the healthcare providers.

Moreover, companies contributing in the market of heart failure treatment drugs are facing issues on several fronts due to the epidemic. These main issues have disturbed distribution of raw materials that are required for production of drug formulation as a result of irregular transportation. Furthermore, suppliers of drug products are witnessing uneven demand for their products from retailers.

To learn more about this report, request a sample copy*
* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report@ https://www.coherentmarketinsights.com/insight/request-sample/4172

Hence, the SARS-CoV-2 virus is expected to hinder growth of the UAE heart failure treatment drugs market over the forecast period.

Overview

The eligible drugs for reimbursement are those which are used in treatment of cardiovascular disorders such as ischemia, heart attack, heart failure, and others. Furthermore, UAE’s regulatory authorities have taken initiatives to minimize the cost of treatment for the patients. In February 2020, UAE’s Ministry of Health and Prevention had decreased the cost of around 573 medicines that are used for treatment of diabetes, cardiovascular diseases, respiratory and nerves diseases from 2 to 74%. The initiative has benefitted the patients with insurance and meagre savings to spend on medical services.

The UAE heart failure treatment drugs market is expected to register a CAGR of 6.5% over the forecast period (2020-2027) and is expected to be valued at US$ 62.8 million in 2020.

Driver

Rising expenditure on healthcare sector is expected to propel growth of the UAE heart failure treatment drugs market over the forecast period. As per the Dubai Export 2019, the following report was prepared by World Bank, International Trade Center, and Fitch Solution.

In 2019 and 2020, the healthcare forecast for UAE was US$ 15.3 billion and US$ 16.8 billion respectively.

In 2019 and 2020, the pharmaceutical expenditure for UAE was US$ 5.9 billion and US$ 6.2 billion respectively.

Market Taxonomy

• According to the Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies.
• According to the class of drug: ACE Inhibitors, Angiotensin 2 Receptor Blockers, Beta Blockers, Diuretics, Aldosterone Antagonists, Inotropes, Others.

Access research reports that are tailored specifically for you and your organization in order to explore practical growth strategies and recommendations
Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/4172

Restraints

The Middle Eastern countries such as Saudi Arabia and UAE have a strict guidelines and regulations for their pharmaceutical providers as compared to other nations across the globe.

Several pharmaceutical legislative information of the Middle Eastern region cannot be accessed by any private or public pharmaceutical company around the world. Furthermore, the legislations are only available in native language which makes the comprehension more complex for the international pharmaceutical players for launching their products in this region.

Furthermore, registration of fewer products by international pharmaceutical companies in the Middle Eastern nations such as Saudi Arabia and UAE, might lead to scarcity of medical and pharmaceutical products in these countries.

Competitive Landscape

Key companies contributing in the UAE heart failure treatment drugs market include GlaxoSmithKline Plc., Teva Pharmaceutical Industries Ltd, Amgen, Inc., Pfizer, Novartis International AG, AstraZeneca Plc., Bristol-Myers Squibb, Mylan N.V., and Merck & Co., Inc.

Read Press Release: https://www.coherentmarketinsights.com/press-release/uae-heart-failure-drugs-treatment-market-3427

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website – www.coherentmarketinsights.com

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837